Evidence map›Paper›PMID 35946495›Full record

ArticleBioconjugate chemistry2022

Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.

Samantha M Sarrett, Cindy Rodriguez, Grzegorz Rymarczyk, Meena M Hosny, Outi Keinänen, Samantha Delaney, Sarah Thau, Benjamin A Krantz, Brian M Zeglis

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Site-specific bioconjugation and nuclear imaging.Current opinion in chemical biology · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Samantha M SarrettDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
Cindy RodriguezDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
Grzegorz RymarczykAdvanced Proteome Therapeutics Inc, Boston, Massachusetts 02118, United States.
Meena M HosnyDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
Outi KeinänenDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.ORCID 0000-0002-3939-6706
Samantha DelaneyDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
Sarah ThauDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
Benjamin A KrantzAdvanced Proteome Therapeutics Inc, Boston, Massachusetts 02118, United States.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.ORCID 0000-0002-9091-744X
The Graduate Center, CUNY · USCity University of New York · USProteostasis Therapeutics (United States) · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Pretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5M
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
The Ivis Spectrum CT for Pre-Clinical Oncology ResearchS10OD016207 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2013 to 2013
$595k
SHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499k
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme DiseaseR21EB030275 · NIBIB · HUNTER COLLEGE · PI QIU, WEIGANG, ZEGLIS, BRIAN MATTHEW · 2020 to 2021
$429k
Harnessing PET to Study the In Vivo Fate and Health Effects of Micro- and NanoplasticsK99ES034053 · NIEHS · HUNTER COLLEGE · PI KEINAENEN, OUTI MARIA · 2022 to 2022
$111k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204167NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS U01 CA221046NCRR NIH HHS S10 RR020892NIBIB NIH HHS R21 EB030275NIEHS NIH HHS K99 ES034053NIH HHS S10 OD016207
6 · The paper itself

Abstract

The synthesis of radioimmunoconjugates via the stochastic attachment of bifunctional chelators to lysines can yield heterogeneous products with suboptimal

Indexed as

Breast NeoplasmsImmunoconjugatesAlkynesAnimalsAntibodies, MonoclonalAzidesCell Line, TumorChelating AgentsDeferoxamineEstersFemaleHumansLysineMaleimidesMiceMice, NudeAlkynesAntibodies, MonoclonalAzidesChelating AgentsDeferoxamineEstersImmunoconjugatesLysineMaleimidesSulfhydryl CompoundsZirconium

Identifiers

PMID35946495
PMCPMC10244945
OpenAlexW4296698530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.